SOUTH SAN FRANCISCO, Calif., April 3, 2026
Denali Therapeutics Inc. announced it has regained full global rights to its investigational therapy DNL593 (PTV:PGRN) following the termination of its collaboration with Takeda, marking a significant strategic shift in the company’s neurodegenerative disease pipeline. The decision, described as strategic and not related to safety or efficacy, allows Denali to independently advance the program targeting frontotemporal dementia with granulin mutations (FTD-GRN), a condition with no currently approved disease-modifying treatments.
Strategic Control Strengthens Neurodegenerative Pipeline
By regaining full ownership of DNL593, Denali now holds complete control over clinical development, regulatory strategy, and commercialization pathways, enabling greater flexibility in advancing its precision medicine approach for neurodegenerative diseases. The therapy utilizes the company’s proprietary TransportVehicle™ (TV) platform, designed to cross the blood-brain barrier (BBB)—a major challenge in central nervous system drug delivery.
As highlighted on page 1, this platform enables targeted delivery of progranulin to the brain, addressing the underlying genetic deficiency in FTD-GRN. This strategic move positions Denali to accelerate innovation and maximize long-term value, particularly in a highly competitive neuroscience landscape.
Promising Clinical Data Supports Continued Development
Advertisement
DNL593 is currently being evaluated in an ongoing Phase 1/2 clinical trial, with results expected by the end of 2026. The study has completed enrollment of 40 patients with FTD-GRN, reflecting steady clinical progress. Interim findings from early-stage trials demonstrated dose-dependent increases in cerebrospinal fluid progranulin levels, confirming effective brain delivery of the therapy.
Importantly, the treatment has shown a favorable safety and tolerability profile, with no significant safety concerns reported to date. These findings provide strong scientific validation of Denali’s BBB-crossing technology and reinforce the potential of DNL593 as a first-in-class therapeutic option for patients suffering from this devastating disease.
Innovative Platform Targets Unmet Medical Need
Frontotemporal dementia (FTD) is one of the leading causes of early-onset dementia, particularly affecting individuals under the age of 60. The disease is characterized by progressive cognitive decline, behavioral changes, and loss of motor function, with limited treatment options available. Mutations in the GRN gene, leading to reduced levels of progranulin, are among the most common genetic drivers of FTD.
Denali’s TransportVehicle™ platform, as described in the technical overview on page 1, enables enhanced delivery of biologics across the BBB, achieving 10- to 30-fold greater brain exposure for antibodies and up to 1,000-fold for oligonucleotides compared to conventional approaches. This breakthrough technology has the potential to transform treatment paradigms across multiple central nervous system disorders, positioning Denali at the forefront of next-generation biotherapeutics.
Future Outlook and cGxP-Aligned Development Strategy
With full control of DNL593, Denali is expected to accelerate clinical development under strict cGxP frameworks, ensuring compliance with regulatory standards including GLP, GMP, and GCP throughout the drug development lifecycle. The company’s robust pipeline, supported by a clinically validated delivery platform, underscores its commitment to addressing high unmet medical needs in neurodegenerative diseases.
Upcoming clinical readouts in 2026 will be critical in determining the therapy’s path toward late-stage trials and potential regulatory submissions. This milestone reinforces Denali’s leadership in BBB-targeted therapeutics and highlights the growing importance of innovative delivery technologies in modern drug development.
Source: Denali Therapeutics press release
